New collaboration for Immutep

Latest News

Immutep (ASX:IMM) has entered into a clinical trial collaboration agreement, a supply agreement and a service agreement with CYTLIMIC for its lead product candidate eftilagimod alpha ('efti') as part of a cancer vaccine.

The company said the agreements enable the two parties to collaborate on clinical trials to evaluate efti as part of a therapeutic cancer vaccine containing CYTLIMIC’s cancer peptide vaccine, called CYT001.

The trials will be conducted by and are under the control of CYTLIMIC who will fully fund all development costs.

Under the collaboration agreement, Immutep will receive an upfront payment of US$500,000 and is eligible to receive up to US$4.5 million in milestone payments upon the achievement of milestones by CYTLIMIC.

This therapeutic cancer vaccine is the third example of where efti is being evaluated in clinical studies in a combination.

Immutep said it retains complete exclusivity over its patent rights covering its own clinical development programs and those it is conducting in conjunction with its other collaboration partners evaluating IMP321 in combination with either chemotherapy (AIPAC trial) or PD-1/PD-L1 immunotherapy (INSIGHT and TACTI trials).

Under the supply agreement, Immutep will provide efti to CYTLIMIC for the manufacture of CYT001 for use in the clinical development and commercialisation of the vaccine. The Parties have also entered into a service agreement where Immutep will provide technical support services to CYTLIMIC during the development and commercialisation of CYT001.

According to Immutep CEO Marc Voigt, “We are very excited to be working alongside CYTLIMIC to help evaluate efti as part of an innovative cancer vaccine that has potential as a new therapy.

"Efti is generating interest globally. Following the agreements with CYTLIMIC, it is now being evaluated as part of three different combination therapy types: as part of a therapeutic cancer vaccine, as a chemo-immunotherapy and in an IO combination, showing its broad therapeutic potential.”

“We are delighted with the engagement with Immutep, which will strongly help realize an innovative cancer vaccine-immunotherapy," said CYTLIMIC President and CEO, Dr Shun Doi. “Our own studies have shown that the combination of LAG-3Ig and Poly IC synergistically boost the efficacy of peptide vaccine, and thus I believe the combination of efti in our vaccine CYT001, which is also unique as an application of artificial intelligence, is an important step to add a new solution in the cancer immunotherapy world.”